Forte Biosciences Files 8-K: Director Changes & Officer Compensation
Ticker: FBRX · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1419041
Sentiment: neutral
Topics: management-change, compensation, corporate-governance
Related Tickers: FBRX
TL;DR
Forte Bio (FBRX) board shakeup, exec pay changes, and shareholder votes filed today.
AI Summary
On January 24, 2025, Forte Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of a new director, and adjustments to compensatory arrangements for certain officers. Additionally, the filing includes information regarding the submission of matters to a vote of security holders and the filing of financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directorship and executive compensation can indicate internal shifts that may affect future performance or strategy.
Key Numbers
- 20250124 — Filing Date (Date of the 8-K filing)
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- January 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-38052 (company_id) — Commission File Number
- 26-1243872 (tax_id) — IRS Employer Identification No.
- 3060 Pegasus Park Dr. Building 6 Dallas, Texas 75247 (address) — Address of Principal Executive Offices
FAQ
Who is the departing director and who is the newly elected director?
The filing does not specify the names of the departing or newly elected directors, only that these events occurred.
What specific changes were made to the compensatory arrangements of certain officers?
The filing indicates that there were adjustments to compensatory arrangements, but the specific details of these adjustments are not provided in this summary section.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.
Are the financial statements and exhibits being filed as part of this report?
Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item information, indicating they are included.
What is the company's principal business address?
The company's principal executive offices are located at 3060 Pegasus Park Dr. Building 6, Dallas, Texas 75247.
Filing Stats: 846 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-01-24 16:33:01
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
Filing Documents
- d875887d8k.htm (8-K) — 30KB
- d875887dex101.htm (EX-10.1) — 92KB
- 0001193125-25-012236.txt ( ) — 267KB
- fbrx-20250124.xsd (EX-101.SCH) — 3KB
- fbrx-20250124_lab.xml (EX-101.LAB) — 18KB
- fbrx-20250124_pre.xml (EX-101.PRE) — 11KB
- d875887d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: January 24, 2025 By: /s/ Antony Riley Antony Riley Chief Financial Officer